Cargando…

Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units

Background: Circulating CD34+ progenitor cells (CD34+CPCs) are characterized by pronounced tissue regeneration activity. Dyslipidemic subjects seemed to have reduced CD34+CPCs, and statin therapy appeared to restore their levels. We aimed to evaluate the effects of PCSK9 inhibitors (PCSK9-i) on CD34...

Descripción completa

Detalles Bibliográficos
Autores principales:	Scicali, Roberto, Mandraffino, Giuseppe, Scuruchi, Michele, Lo Gullo, Alberto, Di Pino, Antonino, Ferrara, Viviana, Morace, Carmela, Aragona, Caterina Oriana, Squadrito, Giovanni, Purrello, Francesco, Piro, Salvatore
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312801/ https://www.ncbi.nlm.nih.gov/pubmed/35885020 http://dx.doi.org/10.3390/biomedicines10071715

Ejemplares similares

PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy
por: Toscano, Arianna, et al.
Publicado: (2022)

Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting
por: Scicali, Roberto, et al.
Publicado: (2021)

May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?
por: Scicali, Roberto, et al.
Publicado: (2020)

Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience
por: Scicali, Roberto, et al.
Publicado: (2020)

Direct and indirect effects of SARS-CoV-2 pandemic in subjects with familial hypercholesterolemia: A single lipid-center real-world evaluation
por: Scicali, R., et al.
Publicado: (2022)

Direct and Indirect Effects of SARS-CoV-2 Pandemic in Subjects with Familial Hypercholesterolemia: A Single Lipid-Center Real-World Evaluation
por: Scicali, Roberto, et al.
Publicado: (2021)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

Fatty Liver as Potential Biomarker of Atherosclerotic Damage in Familial Combined Hyperlipidemia
por: Mandraffino, Giuseppe, et al.
Publicado: (2022)

Circulating progenitor cells in hypertensive subjects: Effectiveness of a treatment with olmesartan in improving cell number and miR profile in addition to expected pharmacological effects
por: Mandraffino, Giuseppe, et al.
Publicado: (2017)

Management of Statin Intolerant Patients in the Era of Novel Lipid Lowering Therapies: A Critical Approach in Clinical Practice
por: Bosco, Giosiana, et al.
Publicado: (2023)

Endocan and Circulating Progenitor Cells in Women with Systemic Sclerosis: Association with Inflammation and Pulmonary Hypertension
por: Lo Gullo, Alberto, et al.
Publicado: (2021)

Expression and Change of miRs 145, 221 and 222 in Hypertensive Subjects Treated with Enalapril, Losartan or Olmesartan
por: Mandraffino, Giuseppe, et al.
Publicado: (2021)

Endothelial Progenitor Cells for Diagnosis and Prognosis in Cardiovascular Disease
por: Aragona, Caterina Oriana, et al.
Publicado: (2016)

Arterial Stiffness and Adult Onset Vasculitis: A Systematic Review
por: Lo Gullo, Alberto, et al.
Publicado: (2022)

Serum endocan as a predictive biomarker of cardiovascular risk in obese pediatric patients
por: Morace, Carmela, et al.
Publicado: (2023)

LDL‐cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid‐lowering therapy
por: Hamasaki, Masato, et al.
Publicado: (2021)

Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation
por: Scicali, Roberto, et al.
Publicado: (2019)

Abnormal left ventricular global strain during exercise-test in young healthy smokers
por: Mandraffino, Giuseppe, et al.
Publicado: (2020)

Low-density lipoprotein cholesterol outcomes post-non-PCSK9i lipid-lowering therapies in atherosclerotic cardiovascular disease and probable heterozygous familial hypercholesterolemia patients
por: Chen, Chi-Chang, et al.
Publicado: (2018)

Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview
por: Marchisello, Simona, et al.
Publicado: (2019)

Quality of Life (QoL) in Patients with Chronic Inflammatory Bowel Diseases: How Much Better with Biological Drugs?
por: Bellone, Federica, et al.
Publicado: (2023)

Genetic Polymorphisms in LDLR, APOB, PCSK9 and Other Lipid Related Genes Associated with Familial Hypercholesterolemia in Malaysia
por: Lye, Say-Hean, et al.
Publicado: (2013)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells
por: Filippello, Agnese, et al.
Publicado: (2020)

Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD
por: Di Mauro, Stefania, et al.
Publicado: (2021)

Implementation of Novel Lipid Therapies in a Refractory Heterozygous Familial Hypercholesterolemia Patient With Atherosclerotic Disease
por: Weintraub, Spencer F., et al.
Publicado: (2022)

PCSK9 and Atherosclerosis - Lipids and Beyond
por: Shapiro, Michael D., et al.
Publicado: (2017)

Familial Hypercholesterolemia: The Lipids or the Genes?
por: Fahed, Akl C, et al.
Publicado: (2011)

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile
por: Lupo, Maria Giovanna, et al.
Publicado: (2021)

Chronic Exposure to Palmitate Impairs Insulin Signaling in an Intestinal L-cell Line: A Possible Shift from GLP-1 to Glucagon Production
por: Filippello, Agnese, et al.
Publicado: (2018)

1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease
por: Di Pino, Antonino, et al.
Publicado: (2019)

Budget Impact Analysis of PCSK9 Inhibitors for the Management of Adult Patients with Heterozygous Familial Hypercholesterolemia or Clinical Atherosclerotic Cardiovascular Disease
por: Mallya, Usha G., et al.
Publicado: (2017)

PCSK9 targets important for lipid metabolism
por: Schulz, Rainer, et al.
Publicado: (2017)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

Familial Hypercholesterolemia and the Atherosclerotic Disease
por: Kim, Yoo Ri, et al.
Publicado: (2013)

An update on lipid apheresis for familial hypercholesterolemia
por: Taylan, Christina, et al.
Publicado: (2022)

Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy
por: Urbano, Francesca, et al.
Publicado: (2019)

Controlling Nutritional Status (CONUT) Score as a Potential Prognostic Indicator of In-Hospital Mortality, Sepsis and Length of Stay in an Internal Medicine Department
por: Miano, Nicoletta, et al.
Publicado: (2023)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_l5dvfa6tpjv90p4q24oudf3lge